For cardiovascular death, the effects of allocation to an SGLT-2 inhibitor appeared larger in the EMPA-REG OUTCOME trial compared to the other trials in people with type 2 DM at high ASCVD risk (het p=0.01; Figure 3), but there was no heterogeneity of effects among HF trials (het p=0.80) or CKD trials (het p=0.67). This evidence concerns the gene SLC5A2 and chronic kidney disease.